76 related articles for article (PubMed ID: 10357467)
1. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.
Raez L; Cabral L; Cai JP; Landy H; Sfakianakis G; Byrne GE; Hurley J; Scerpella E; Jayaweera D; Harrington WJ
AIDS Res Hum Retroviruses; 1999 May; 15(8):713-9. PubMed ID: 10357467
[TBL] [Abstract][Full Text] [Related]
2. Drug combination treats brain cancer.
AIDS Patient Care STDS; 1999 Dec; 13(12):755. PubMed ID: 10743546
[No Abstract] [Full Text] [Related]
3. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma.
Aboulafia DM
Clin Infect Dis; 2002 Jun; 34(12):1660-2. PubMed ID: 12032910
[No Abstract] [Full Text] [Related]
4. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
Aboulafia DM; Ratner L; Miles SA; Harrington WJ;
Clin Lymphoma Myeloma; 2006 Mar; 6(5):399-402. PubMed ID: 16640817
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.
Marretta L; Stocker H; Drauz D; Mueller M; Masuhr A; Dieckmann S; Wong V; Koch A; Grueneisen A; Arastéh K; Weiss R
Eur J Med Res; 2011 May; 16(5):197-205. PubMed ID: 21719392
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
[TBL] [Abstract][Full Text] [Related]
7. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
[TBL] [Abstract][Full Text] [Related]
8. New combination for brain cancer.
TreatmentUpdate; 1999 Aug; 11(6):4-6. PubMed ID: 11366935
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system.
Slobod KS; Taylor GH; Sandlund JT; Furth P; Helton KJ; Sixbey JW
Lancet; 2000 Oct; 356(9240):1493-4. PubMed ID: 11081539
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.
Bayraktar UD; Diaz LA; Ashlock B; Toomey N; Cabral L; Bayraktar S; Pereira D; Dittmer DP; Ramos JC
Leuk Lymphoma; 2014 Apr; 55(4):786-94. PubMed ID: 23837493
[TBL] [Abstract][Full Text] [Related]
11. Primary CNS lymphoma in HIV infection.
Brandsma D; Bromberg JEC
Handb Clin Neurol; 2018; 152():177-186. PubMed ID: 29604975
[TBL] [Abstract][Full Text] [Related]
12. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
13. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy.
McGowan JP; Shah S
AIDS; 1998 May; 12(8):952-4. PubMed ID: 9631151
[No Abstract] [Full Text] [Related]
14. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas.
Lee RK; Cai JP; Deyev V; Gill PS; Cabral L; Wood C; Agarwal RP; Xia W; Boise LH; Podack E; Harrington WJ
Cancer Res; 1999 Nov; 59(21):5514-20. PubMed ID: 10554028
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection.
Sasakawa A; Hirase C; Yamaguchi T; Morita Y; Miyatake J; Matsumura I; Maeda Y
Hematology; 2012 May; 17(3):144-50. PubMed ID: 22664113
[TBL] [Abstract][Full Text] [Related]
16. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
Cingolani A; Fratino L; Scoppettuolo G; Antinori A
J Neurovirol; 2005; 11 Suppl 3():38-44. PubMed ID: 16540454
[TBL] [Abstract][Full Text] [Related]
17. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
18. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Mentzer SJ; Fingeroth J; Reilly JJ; Perrine SP; Faller DV
Blood Cells Mol Dis; 1998 Jun; 24(2):114-23. PubMed ID: 9628848
[TBL] [Abstract][Full Text] [Related]
19. AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas.
Tosi P; Gherlinzoni F; Visani G; Coronado O; Costigliola P; Mazzetti M; Gritti F; Chiodo F
Leuk Lymphoma; 1998 Jun; 30(1-2):175-9. PubMed ID: 9669687
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
